Shenzhen Haibin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Joincare Pharmaceutical Group Co., Ltd. (stock code: 600380). It was established in 1989 and officially put into operation in 1992 with a registered capital of 700 million RMB. The factory covers an area of 16,000 square meters. 26,800 m2. The company is located in the national eco-environmental demonstration zone
Since its establishment, Shenzhen Haibin Pharmaceutical Co., Ltd. has been adhering to the diligent, pioneering, rigorous and efficient enterprise spirit and people-oriented business philosophy. After more than ten years of hard work, it has achieved remarkable results. It has successively won the title of Shenzhen Advanced Technology Enterprise and Guangdong Province Technology Innovation Advantage Enterprise; in 2001, it was awarded as “Shenzhen High-tech Enterprise”; in 2003, it was rated as “Green Enterprise” in Shenzhen; in 2004, it was assured by Guangdong Province Food and Drug The Engineering Evaluation Committee identified it as “Guangdong Province Food and Drug Relief Engineering Demonstration Base”. The company has grown into a large and medium-sized modern pharmaceutical industry enterprise with a sales volume of over 300 million yuan for medium and large enterprises with more than 500 employees.
Shenzhen Haibin Pharmaceutical Co., Ltd. mainly produces antibiotics, and its business scope includes chemical raw materials and preparations, antibiotics, cardiovascular drugs, and proprietary Chinese medicines. There are many production lines that comply with GMP standards, such as penicillin and cephalosporin powder production line, carbapenem raw material drug production line, freeze-dried raw material and preparation production line, chemical raw material drug production line, penicillin and chemical oral drug production line. Wait. The main varieties are: meropenem, imipenem, faropenem, beenergy, quick energy, piperacillin sodium tazobactam sodium for injection, desloratadine tablets, irbesartan tablets, etc.; The production capacity of powder injection injection is 80 million bottles, 100 million tablets, 100 million capsules and 30 tons of raw materials.
New product development and process improvement are the driving force for the sustainable development of the company and one of our core competitiveness. Shenzhen Haibin Pharmaceutical Co., Ltd. began research on a new generation of high-efficiency broad-spectrum antibacterial drug, carbapenem antibiotics, in 1999. The first developed Meiropeon process route is difficult to synthesize and the process is unstable. At the initial stage of production, the cost of raw materials is as high as 200,000 yuan per kilogram, which has no commercial value at all. After several years of continuous efforts by R&D personnel, not only the production cost has been reduced to the current low, but also the product quality has been further improved, and the quality of the raw materials and their preparations have reached the standards of the United States Pharmacopoeia, greatly improving the market for the product. Competitive, it has a number of Chinese patents and world patents related to the production process of Meropen. At present, the company regards the carbapenem series of antibiotics as the key research and development direction, not only basically completes the technological research of new drugs such as imipenem, faropenem and biapenem, and the raw materials and branches of the products. Great optimization and innovation have also been carried out. As a brand-name product in today's antibiotics, this series of products has a surprising effect on uncontrollable infections. Its successful development not only brings new and longer-term profit growth points to the company, but also will certainly write Chinese antibiotics. a new chapter.
"Based on the domestic and the world" is a major strategic goal of Shenzhen Haibin Pharmaceutical Co., Ltd. Through unremitting efforts, the export of Meropenem raw materials in 2003 began, and in 2006, the export volume reached 1.3 tons. In just a few years, the drug product was ranked first in the world in terms of sales volume, and the products were exported. Southeast Asia, Africa, the Middle East, South America and other places. In 2006, imipenem cilastatin sodium API has also begun to export to countries such as India and Brazil.
Expanding the broader market space of products and exporting products to regulated markets such as Europe and the United States is the next goal of our efforts. To achieve this goal, COS and FDA certification are the only ways. In December 2006, we signed a cooperation agreement with a German company on COS certification, which opened the curtain for entering the European and American markets.
Quality is life. Shenzhen Haibin Pharmaceutical Co., Ltd. has established a quality management system that fully complies with GMP requirements. The Quality Department is responsible for the operation of drug inspection and the company's quality assurance system. Quality management personnel account for about 12% of the total number of employees, of which 50% have bachelor degree or above. The laboratory has a complete function room, such as a sterile measurement room, a microbial limit detection room, etc., and is equipped with advanced inspection instruments and equipment such as high-performance liquid chromatography, gas chromatography, infrared spectrophotometer, etc. The detection needs.
As a member of the pharmaceutical industry, we are duty-bound to develop the pharmaceutical industry and safeguard human health. We believe that as long as we adhere to the goal of "sincerely dedicating ourselves to a healthy cause" and adhering to the style of "care for love and rigorousness and seriousness", continuous innovation and hard work, Haibin Pharmaceutical will become a bright pearl in the Chinese pharmaceutical industry.